Chemicalinfo Chemlink Pharm-Chem Net

FDA Approved Drugs During 2008The FDA's drug approval process is one that has critics on both sides. The drugmakers often complain that the agency is too slow and too cautious. Critics of the drugmakers often feel that the companies just aren't pumpi...

新药物或可增强伊马替尼抗白血病效果Potential New Way To Make A Good Anti-leukemia Drug Even Betterhttp://www.sciencedaily.com/releases/2008/10/081020093402.htmScienceDaily (Oct. 21, 2008) — A recently identified cancer-causing protein makes the anti-leukemia dru...

 两部门通知: 11月1日起将提高部分商品出口退税率2008年10月21日　　 来源：财政部网站近日，经国务院批准，财政部、国家税务总局发出《关于提高部分商品出口退税率的通知》，明确从2008年11月1日起，适当调高部分劳动密集型和高技术含量、高附加值商品的出口退税率。具体为：将部分纺织品、服装、玩具出口退税率提高到14%；将日用及艺术陶瓷出口退税率提高到11%；将部分塑料制品出口退税率提高到9%；将部分家具出口退税率分别提高到11%、13%；将艾滋病药物、基因重组人胰岛素冻干粉、黄胶...

WuXi misses Q3 goals due to “drop in R&D spending”By Gareth Macdonald14-Oct-2008 - China’s WuXi PharmaTech has reported a below par set of unaudited third quarter results and has cut its full-year expectations blaming the curre...

A Report on Brazil's Pharmaceuticals and Healthcare Market for Q3 2008 - Examine the Opportunities in One of the Largest & Most Dynamic Markets in the World

Mere weeks after signing major strategic collaborations with contract service firms Covance, Quintiles and 3i, Eli Lilly has journeyed further down the outsourcing route – albeit with a different spin – by forging another agreement with India's Jubilant Organosys...

India-based Piramal Healthcare has extended the range of early phase drug product development and manufacturing on offer at its Morpeth, UK facility...

Zentiva board accepts Sanofi's revised Euro1.8bn offer, 23-Sep-2008 - Sanofi-Aventis' EUROs1.8bn ($2.6bn) offer for Czech generics firm Zentiva has been unanimously accepted by the latter firm's board after four months of wrangling that has seen the bid increase by 9.5 per cent.

Novartis/Schering AG To Introduce Vatalanib For The Second-line Treatment Of Patients With Metastatic Colorectal CancerApril 20, 2007Vatalanib (PTK787) Novartis/Schering AG Vatalanib is predicted to reach the market in early 2008 for the second-line...

Brazil, Gilead agree AIDS drug price cut Associated PressMay 10, 2006 Gilead Sciences will slash by half the price of its drug tenofovir, used in an anti-AIDS cocktail, Brazil's Health Ministry said. The deal will save annually 15.2 million do...